Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:3355 |
| Name | fibrosarcoma |
| Definition | A connective tissue cancer that has_material_basis_in fibrous connective tissue and characterized by the presence of immature proliferating fibroblasts or undifferentiated anaplastic spindle cells in a storiform pattern. |
| Source | DiseaseOntology.org |
| Alt Ids | DOID:3509 DOID:156 |
| Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer fibrosarcoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| TP53 wild-type | Pegylated liposomal doxorubicin + RO6839921 | fibrosarcoma | sensitive | detail... |
| IDH1 R132C | Vorasidenib | fibrosarcoma | predicted - sensitive | detail... |
| IDH1 R132C | Ceralasertib + Olaparib | fibrosarcoma | sensitive | detail... |
| ALK R401* | Crizotinib | fibrosarcoma | predicted - sensitive | detail... |
| ALK V757M | Crizotinib | fibrosarcoma | predicted - sensitive | detail... |
| NRAS Q61K | Palbociclib + Trametinib | fibrosarcoma | sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT00356031 | Phase II | Bevacizumab | Bevacizumab and Radiation Therapy for Sarcomas | Completed | USA | 0 |
| NCT01981551 | Phase II | Nirogacestat | Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis | Completed | USA | 0 |
| NCT02275286 | Phase Ib/II | Trabectedin | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) | Recruiting | ITA | FRA | ESP | 0 |
| NCT02584309 | Phase II | Dexrazoxane Doxorubicin + Olaratumab | Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | Completed | USA | 0 |
| NCT02923778 | Phase II | Talimogene laherparepvec | Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery | Active, not recruiting | USA | CAN | 0 |
| NCT03009201 | Phase I | Doxorubicin + Ribociclib | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery | Completed | USA | 0 |
| NCT03092323 | Phase II | Pembrolizumab | A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032) | Active, not recruiting | USA | ITA | CAN | AUS | 0 |
| NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | CHE | 1 |
| NCT03860207 | Phase Ib/II | Hu3F8-BsAb | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | Terminated | USA | 0 |
| NCT04028063 | Phase II | Botensilimab + Doxorubicin Balstilimab + Doxorubicin + Zalifrelimab | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | Recruiting | USA | 0 |
| NCT04420975 | Phase I | BO-112 + Nivolumab | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
| NCT04741438 | Phase III | Ipilimumab + Nivolumab Pazopanib | Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) | Unknown status | FRA | 0 |
| NCT05809830 | Phase Ib/II | Doxorubicin Doxorubicin + LB-100 | Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas (Enhancer) | Active, not recruiting | ESP | 0 |
| NCT05879185 | Phase II | Izuralimab | A Study of XmAb23104 in People With Sarcoma | Terminated | USA | 0 |
| NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Active, not recruiting | BRA | 0 |
| NCT06789172 | Phase I | OKN4395 + Pembrolizumab OKN4395 Famotidine + OKN4395 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors (INVOKE) | Recruiting | USA | GBR | AUS | 0 |
| NCT07089992 | Phase II | Pembrolizumab | A Study of Pembrolizumab in People With Ultra-Rare Sarcomas | Not yet recruiting | USA | 0 |